Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Shares Repurchased (2016 - 2026)

Amphastar Pharmaceuticals has reported Shares Repurchased over the past 13 years, most recently at $20.5 million for Q4 2025.

  • For Q4 2025, Shares Repurchased fell 51.15% year-over-year to $20.5 million; the TTM value through Dec 2025 reached $75.6 million, down 40.46%, while the annual FY2025 figure was $75.6 million, 11.55% down from the prior year.
  • Shares Repurchased for Q4 2025 was $20.5 million at Amphastar Pharmaceuticals, up from $4.8 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $50.0 million in Q3 2023 and troughed at $128000.0 in Q2 2023.
  • A 5-year average of $16.4 million and a median of $11.0 million in 2025 define the central range for Shares Repurchased.
  • On a YoY basis, Shares Repurchased climbed as much as 552.16% in 2023 and fell as far as 97.91% in 2023.
  • Year by year, Shares Repurchased stood at $13.4 million in 2021, then skyrocketed by 34.48% to $18.1 million in 2022, then soared by 176.72% to $50.0 million in 2023, then decreased by 16.0% to $42.0 million in 2024, then plummeted by 51.15% to $20.5 million in 2025.
  • Business Quant data shows Shares Repurchased for AMPH at $20.5 million in Q4 2025, $4.8 million in Q3 2025, and $39.2 million in Q2 2025.